MARKET

AMTI

AMTI

Applied Molecular Transport Inc.
NASDAQ
0.6044
-0.0152
-2.45%
After Hours: 0.5700 -0.0344 -5.69% 17:24 02/07 EST
OPEN
0.6100
PREV CLOSE
0.6196
HIGH
0.6100
LOW
0.5675
VOLUME
110.79K
TURNOVER
0
52 WEEK HIGH
8.76
52 WEEK LOW
0.3299
MARKET CAP
23.54M
P/E (TTM)
-0.1746
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 01/12 21:31
B of A Securities Downgrades Applied Molecular to Underperform, Lowers Price Target to $0.5
Benzinga · 01/05 12:07
--BofA Securities Downgrades Applied Molecular Transport to Underperform From Buy, Adjusts Price Target to $0.50 From $5
--BofA Securities Downgrades Applied Molecular Transport to Underperform From Buy, Adjusts Price Target to $0.50 From $5
MT Newswires · 01/05 07:47
Applied Molecular Transport To $2? Here Are Other Price Target Changes For Tuesday
Benzinga · 12/27/2022 17:15
What To Know About SVB Leerink's Downgrade of Applied Molecular
Benzinga · 12/27/2022 17:00
Benzinga's Top Ratings Upgrades, Downgrades For December 27, 2022
Benzinga · 12/27/2022 15:00
SVB Leerink Downgrades Applied Molecular to Market Perform, Lowers Price Target to $2
Benzinga · 12/27/2022 09:36
--SVB Securities Downgrades Applied Molecular Transport to Market Perform From Outperform, Cuts Price Target to $2 From $15
--SVB Securities Downgrades Applied Molecular Transport to Market Perform From Outperform, Cuts Price Target to $2 From $15
MT Newswires · 12/27/2022 06:54
More
About AMTI
Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company. The Company is leveraging its technology platform to design and develop a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The Company is building a portfolio of oral product candidates based on its technology platform, including AMT-101, an oral gastrointestinal (GI)-selective oral fusion of interleukin 10 (IL-10) that has completed a Phase 1b clinical trial in patients with ulcerative colitis (UC). The Company’s other product candidate, AMT-126, is a GI-selective oral fusion of interleukin 22 (IL-22). Its technology platform enables it to design and develop various oral biologic therapeutic modalities, such as peptides, proteins, full-length antibodies, antibody fragments, and ribonucleic acid (RNA) therapeutics with development-stage drugs.

Webull offers kinds of Applied Molecular Transport Inc. stock information, including NASDAQ:AMTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMTI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AMTI stock methods without spending real money on the virtual paper trading platform.